Scaling Production and Managing Risks
Mesenchymal stromal/stem cells (MSCs) are in the forefront of cell therapies for COVID-19 treatment. However, the current COVID-19 pandemic requires rapid deployment of resources that can provide immediate access to MSC based therapeutics.
This webinar will cover challenges and options available for cell therapy product developers in scaling production, including industry best practices that will deliver rapid, safe, and cost-effective solutions to meet this crisis demand.
What you will learn:
Current state of MSC therapies for COVID-19: on-going trials and clinical evidence from ARDS experience
Current limitations and development of technology platforms to support future MSC manufacturing needs
Considerations in manufacturing readiness to support cGMP manufacturing of MSCs